Cargando…

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study

PURPOSE: This study aimed to investigate the prognostic significance of surgery in large-cell neuroendocrine carcinoma (LCNC) patients. METHODS: A total of 453 patients from the Surveillance, Epidemiology, and End Results database diagnosed with stage T1-4N0-2M0 LCNC from 2010 to 2015 were analyzed....

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hao, Xie, Weixia, Li, Xianpeng, Wang, Huaying, Yu, Wan-Jun, Chen, Xiaolu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324150/
https://www.ncbi.nlm.nih.gov/pubmed/37408065
http://dx.doi.org/10.1186/s13019-023-02314-1
_version_ 1785069088070959104
author Jiang, Hao
Xie, Weixia
Li, Xianpeng
Wang, Huaying
Yu, Wan-Jun
Chen, Xiaolu
author_facet Jiang, Hao
Xie, Weixia
Li, Xianpeng
Wang, Huaying
Yu, Wan-Jun
Chen, Xiaolu
author_sort Jiang, Hao
collection PubMed
description PURPOSE: This study aimed to investigate the prognostic significance of surgery in large-cell neuroendocrine carcinoma (LCNC) patients. METHODS: A total of 453 patients from the Surveillance, Epidemiology, and End Results database diagnosed with stage T1-4N0-2M0 LCNC from 2010 to 2015 were analyzed. The propensity-score matching analysis with a ratio of 1:1 was used to minimize the bias effect of other clinical characteristics, and 77 pairs of patients’ data were performed for subsequent statistical analysis. The Cox proportional hazards model, Kaplan-Meier analysis, and Log-rank test were used in the present study. The primary observational endpoint was cancer-specific survival (CSS). RESULTS: The 1-year, 3-year, and 5-year CSS rates were 60.0%, 45.0%, and 42.0% in those 453 LCNC patients. Compared with patients who underwent surgical resection, patients without surgery had a lower 5-year CSS rate (18.0% vs. 52.0%, P < 0.001). After analyses of multivariable Cox regression, chemotherapy, T stage, N stage, and surgery were identified as independent prognostic indicators (all P < 0.05). In the cohort of old patients, the median survival time was longer in cases after surgery than those without surgery (13.0 months vs. NA, P < 0.001). Besides, in patients with different clinical characteristics, the receiving surgery was a protective prognostic factor (all hazard ratio < 1, all P < 0.05). In addition, for the cohort with stage T1-2N0-2M0, patients after the operation had more improved outcomes than patients without surgery (P < 0.001). CONCLUSIONS: We proposed that the surgery could improve the survival outcomes of LCNC patients with stage T1-4N0-2M0. Moreover, old patients could benefit from surgery.
format Online
Article
Text
id pubmed-10324150
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103241502023-07-07 The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study Jiang, Hao Xie, Weixia Li, Xianpeng Wang, Huaying Yu, Wan-Jun Chen, Xiaolu J Cardiothorac Surg Research PURPOSE: This study aimed to investigate the prognostic significance of surgery in large-cell neuroendocrine carcinoma (LCNC) patients. METHODS: A total of 453 patients from the Surveillance, Epidemiology, and End Results database diagnosed with stage T1-4N0-2M0 LCNC from 2010 to 2015 were analyzed. The propensity-score matching analysis with a ratio of 1:1 was used to minimize the bias effect of other clinical characteristics, and 77 pairs of patients’ data were performed for subsequent statistical analysis. The Cox proportional hazards model, Kaplan-Meier analysis, and Log-rank test were used in the present study. The primary observational endpoint was cancer-specific survival (CSS). RESULTS: The 1-year, 3-year, and 5-year CSS rates were 60.0%, 45.0%, and 42.0% in those 453 LCNC patients. Compared with patients who underwent surgical resection, patients without surgery had a lower 5-year CSS rate (18.0% vs. 52.0%, P < 0.001). After analyses of multivariable Cox regression, chemotherapy, T stage, N stage, and surgery were identified as independent prognostic indicators (all P < 0.05). In the cohort of old patients, the median survival time was longer in cases after surgery than those without surgery (13.0 months vs. NA, P < 0.001). Besides, in patients with different clinical characteristics, the receiving surgery was a protective prognostic factor (all hazard ratio < 1, all P < 0.05). In addition, for the cohort with stage T1-2N0-2M0, patients after the operation had more improved outcomes than patients without surgery (P < 0.001). CONCLUSIONS: We proposed that the surgery could improve the survival outcomes of LCNC patients with stage T1-4N0-2M0. Moreover, old patients could benefit from surgery. BioMed Central 2023-07-05 /pmc/articles/PMC10324150/ /pubmed/37408065 http://dx.doi.org/10.1186/s13019-023-02314-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiang, Hao
Xie, Weixia
Li, Xianpeng
Wang, Huaying
Yu, Wan-Jun
Chen, Xiaolu
The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title_full The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title_fullStr The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title_full_unstemmed The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title_short The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
title_sort survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324150/
https://www.ncbi.nlm.nih.gov/pubmed/37408065
http://dx.doi.org/10.1186/s13019-023-02314-1
work_keys_str_mv AT jianghao thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT xieweixia thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT lixianpeng thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT wanghuaying thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT yuwanjun thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT chenxiaolu thesurvivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT jianghao survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT xieweixia survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT lixianpeng survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT wanghuaying survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT yuwanjun survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy
AT chenxiaolu survivalbenefitfromsurgeryonpatientswithlargecellneuroendocrinecarcinomainthelungapropensityscorematchingstudy